C
39.43
-0.04 (-0.10%)
| Previous Close | 39.47 |
| Open | 39.48 |
| Volume | 1,713,141 |
| Avg. Volume (3M) | 2,596,621 |
| Market Cap | 6,098,326,528 |
| Price / Sales | 357.47 |
| Price / Book | 11.60 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bearish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.38 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 31 Mar 2026 | 19,963,157 |
| Index Venture Life Associates Vi Ltd | 31 Dec 2025 | 9,961,789 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Wolfe Research, 1.45%) | Buy |
| Median | 39.00 (-1.09%) | |
| Low | 38.00 (Truist Securities, -3.63%) | Buy |
| Average | 39.00 (-1.09%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 25.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 40.00 (1.45%) | Buy | 26.52 |
| Truist Securities | 29 Jan 2026 | 38.00 (-3.63%) | Buy | 24.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |